METex14 mutations occur primarily in non‐small cell lung cancer and can be targeted by small molecule receptor tyrosine kinase inhibitors such as capmatinib, tepotinib, and crizotinib, a non‐specific multikinase inhibitor [29, 30, 31]. The gene discussed is NTRK1; the disease is lung cancer.